ArticleNeurology. Clinical practice2013
Contraindications to intravenous rtPA for acute stroke: A critical reappraisal.
Article in Neurology. Clinical practice, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Differences in Acute Expression of Matrix Metalloproteinases-9, 3, and 2 Related to the Duration of Brain Ischemia and Tissue Plasminogen Activator Treatment in Experimental Stroke.International journal of molecular sciences · 2024Article
- Article
- Protective Effects of Naringin in Cerebral Infarction and Its Molecular Mechanism.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- Tanshinone inhibits neuronal cell apoptosis and inflammatory response in cerebral infarction rat model.International journal of immunopathology and pharmacology · 2017Article
- Tocilizumab inhibits neuronal cell apoptosis and activates STAT3 in cerebral infarction rat model.Bosnian journal of basic medical sciences · 2016Article
- Contraindications to intravenous rtPA for acute stroke: A critical reappraisal.Neurology. Clinical practice · 2013Article
- Risk Factors Associated With Exclusion of Obese Patients Ischemic Stroke With a History of Smoking From Thrombolysis Therapy.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
- Sex differences in comorbidities associated with exclusion from thrombolytic therapy in ischemic stroke patients with heart failure: A retrospective data analysis.JRSM cardiovascular diseaseArticle
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Only 1%-5% of patients with acute ischemic stroke presenting within 3 hours of symptoms receive IV recombinant tissue plasminogen activator (rtPA)-the only effective treatment available. The administration of rtPA is limited by extensive exclusion criteria, many of which are not based on evidence, but rather derived from expert opinion for large stroke trials. Over the past 15 years, experiences with the use of rtPA in clinical practice have led to evidence suggesting that several of the current contraindications for rtPA are unnecessary and overly restrictive. In this review, we analyze the evidence-most of which is derived from observational research-supporting or contradicting current contraindications for administering IV rtPA to acute ischemic stroke patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.